Literature DB >> 18984414

Patient-reported outcomes including fatigue in primary Sjögren's syndrome.

Simon J Bowman1.   

Abstract

The hallmark of Sjögren's syndrome is focal lymphocytic infiltration of exocrine glands leading to mucosal dryness, particularly of the eyes and mouth. In addition, approximately 70% of patients report fatigue as a particularly prominent and disabling feature associated with reduced health-related quality of life. Other key patient-reported extraglandular symptoms include arthralgia, myalgia, and Raynaud's phenomenon. This article reviews these patient-reported features, their relationships with objective assessment of the disease, potential therapies for these symptoms, and how measurements of these symptoms are relevant to outcome assessment in clinical therapeutic trials.

Entities:  

Mesh:

Year:  2008        PMID: 18984414     DOI: 10.1016/j.rdc.2008.08.010

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  11 in total

1.  Induction of anti-Ro60/anti-La by immunisation with spectrin and induction of anti-spectrin by immunisation with Ro60 and 4-hydroxy-2-nonenal-modified Ro60 immunisation.

Authors:  Biji T Kurien; Yaser Dorri; Michael Bachmann; R Hal Scofield
Journal:  Clin Exp Rheumatol       Date:  2012-12-17       Impact factor: 4.473

2.  A possible genetic association with chronic fatigue in primary Sjögren's syndrome: a candidate gene study.

Authors:  Katrine Brække Norheim; Stephanie Le Hellard; Gunnel Nordmark; Erna Harboe; Lasse Gøransson; Johan G Brun; Marie Wahren-Herlenius; Roland Jonsson; Roald Omdal
Journal:  Rheumatol Int       Date:  2013-09-03       Impact factor: 2.631

3.  Patient reported outcome and experience measures of oral disease in oral medicine.

Authors:  R Ní Ríordáin; P Wiriyakijja
Journal:  Br Dent J       Date:  2017-11-03       Impact factor: 1.626

4.  Primary Sjögren's syndrome in Moroccan patients: characteristics, fatigue and quality of life.

Authors:  Yousra Ibn Yacoub; Samira Rostom; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2011-07-24       Impact factor: 2.631

5.  Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.

Authors:  Katrine Brække Norheim; Erna Harboe; Lasse G Gøransson; Roald Omdal
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

6.  A five-year prospective study of fatigue in primary Sjögren's syndrome.

Authors:  Karstein Haldorsen; Ingvar Bjelland; Anne Isine Bolstad; Roland Jonsson; Johan Gorgas Brun
Journal:  Arthritis Res Ther       Date:  2011-10-13       Impact factor: 5.156

7.  Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations.

Authors:  Belgin Koçer; Mehmet Engin Tezcan; Hale Zeynep Batur; Şeminur Haznedaroğlu; Berna Göker; Ceyla İrkeç; Rümeysa Çetinkaya
Journal:  Brain Behav       Date:  2016-10-13       Impact factor: 2.708

Review 8.  IRE1α Implications in Endoplasmic Reticulum Stress-Mediated Development and Pathogenesis of Autoimmune Diseases.

Authors:  Raghu Patil Junjappa; Prakash Patil; Kashi Raj Bhattarai; Hyung-Ryong Kim; Han-Jung Chae
Journal:  Front Immunol       Date:  2018-06-06       Impact factor: 7.561

9.  Genetic Variants of the BAFF Gene and Risk of Fatigue Among Patients With Primary Sjögren's Syndrome.

Authors:  Christina-Maria Flessa; Evangelia Zampeli; Maria-Eleftheria Evangelopoulos; Vasilis Natsis; Iris L A Bodewes; Erika Huijser; Marjan A Versnel; Haralampos M Moutsopoulos; Clio P Mavragani
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

10.  Peripheral neuropathy and health-related quality of life in patients with primary Sjögren's syndrome: a preliminary report.

Authors:  Marta Jaskólska; Magdalena Chylińska; Anna Masiak; Katarzyna Nowicka-Sauer; Mariusz Siemiński; Marcin Ziętkiewicz; Zenobia Czuszyńska; Zbigniew Zdrojewski
Journal:  Rheumatol Int       Date:  2020-03-14       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.